Cost-effectiveness analysis has to consider all available evidence when informing inputs
暂无分享，去创建一个
Audrey Petitjean | Fabián P Alvarez | Joshua Nealon | Rosalind Hollingsworth | Juan Luis López-Belmonte | A. Petitjean | J. López-Belmonte | J. Nealon | R. Hollingsworth | F. P. Alvarez
[1] L. Demarcus,et al. Comparing influenza vaccine effectiveness between cell-derived and egg-derived vaccines, 2017-2018 influenza season. , 2019, Vaccine.
[2] R. Forshee,et al. Relative effectiveness of influenza vaccines among the U.S. elderly, 2018-19. , 2020, The Journal of infectious diseases.
[3] J. Sampalis,et al. Relative Effectiveness of the Cell-Cultured Quadrivalent Influenza Vaccine Compared to Standard, Egg-derived Quadrivalent Influenza Vaccines in Preventing Influenza-like Illness in 2017–2018 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] R. Forshee,et al. Relative effectiveness of cell-cultured and egg-based influenza vaccines among the U.S. elderly, 2017-18. , 2019, The Journal of infectious diseases.
[5] R. Gani,et al. Estimated cost-effectiveness and burden of disease associated with quadrivalent cell-based and egg-based influenza vaccines in Spain , 2020, Human vaccines & immunotherapeutics.
[6] A. Culyer,et al. Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[7] K. Bruxvoort,et al. Comparison of vaccine effectiveness against influenza hospitalization of cell-based and egg-based influenza vaccines, 2017-2018. , 2019, Vaccine.